Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 3,518 shares of the business's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $18.53, for a total value of $65,188.54. Following the transaction, the chief financial officer directly owned 266,188 shares of the company's stock, valued at $4,932,463.64. This trade represents a 1.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oluyemi Okupe also recently made the following trade(s):
- On Thursday, October 1st, Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.70, for a total value of $59,400.00.
- On Tuesday, September 22nd, Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.95, for a total value of $876,846.15.
- On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.82, for a total value of $354,860.66.
Hims & Hers Health Price Performance
Shares of HIMS traded down $0.43 during mid-day trading on Wednesday, reaching $17.12. The company had a trading volume of 9,531,665 shares, compared to its average volume of 22,172,965. The company's 50 day simple moving average is $27.21 and its 200 day simple moving average is $26.59. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $40.99. The company has a debt-to-equity ratio of 3.85, a quick ratio of 0.84 and a current ratio of 0.92. The company has a market capitalization of $4.01 billion, a price-to-earnings ratio of -20.63 and a beta of 2.53.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.06 by ($0.03). The company had revenue of $890.37 million for the quarter, compared to analyst estimates of $893.13 million. Hims & Hers Health had a negative return on equity of 9.62% and a negative net margin of 6.65%. Hims & Hers Health's revenue for the quarter was up 48.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.06 earnings per share. Analysts expect that Hims & Hers Health, Inc. will post -0.21 EPS for the current year.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Hims & Hers Health in a report on Wednesday, November 4th. Jefferies Financial Group dropped their price objective on shares of Hims & Hers Health from $31.00 to $24.00 and set a "hold" rating for the company in a report on Tuesday, November 10th. Truist Financial boosted their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a report on Monday, August 24th. Bank of America raised their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a "neutral" rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Hims & Hers Health from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $31.53.
Check Out Our Latest Stock Analysis on Hims & Hers Health
Hedge Funds Weigh In On Hims & Hers Health
Several hedge funds and other institutional investors have recently bought and sold shares of HIMS. Versant Capital Management Inc raised its position in shares of Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company's stock worth $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company's stock worth $27,000 after purchasing an additional 319 shares during the period. GK Wealth Management LLC bought a new stake in Hims & Hers Health in the third quarter worth approximately $37,000. Compass Financial Management LLC acquired a new position in Hims & Hers Health in the second quarter valued at approximately $50,000. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Hims & Hers Health during the 2nd quarter worth approximately $147,000. Institutional investors and hedge funds own 63.52% of the company's stock.
Key Headlines Impacting Hims & Hers Health
Investors following HIMS have been watching these headlines:
- Positive Sentiment: Hims & Hers launched Peptides+, adding five provider-guided treatments—sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine—to its telehealth offerings. The company also plans twice-yearly lab testing and ongoing medical-team support through Care+, expanding its services into cellular health and wellness. Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
- Neutral Sentiment: Two insiders, including CFO Oluyemi Okupe, sold shares under pre-arranged Rule 10b5-1 trading plans. The sales may draw investor attention, though the planned nature of the transactions makes them less clear as a signal about current business prospects. CFO transaction filing
- Negative Sentiment: Recent coverage points to pressure from slipping profit and a reported loss of 100,000 subscribers, which may weigh on sentiment even as Hims & Hers adds obesity-drug access and other services. Hims & Hers Stock Fell 32% As Profit Slipped Hims & Hers Lost 100K Subscribers Before Adding Eli Lilly’s $299 Zepbound
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.